Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Biogen Stock Surges After Two Notable Products Walloped Sales Expectations

Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and helped Biogen stock jump.

Investors Business Daily

Experts warn of influx of synthetic opioids amid calls for second Melbourne injecting room

Use of deadly nitazines is on the rise in Australia and a suite of measures is needed to prevent more fatalities, former New Zealand prime minister Helen Clark says

The Guardian - AU

People with MND in England and Wales fear losing access to life-extending drug

NHS cost threshold has not been raised by National Institute for Health and Care Excellence since 2004

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

The Bad News Heading Into AbbVie's First-Quarter Earnings Report

AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.

Investors Business Daily

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investors Business Daily

How Ewing Kauffman Built A Pharma Giant

Kauffman had built Marion Labs into a solid pharmaceutical business. To reach the next level, he knew he needed to take risks.

Investors Business Daily

Exploring The Powerful Benefits Of Natural Health Products Made With Cutting-Edge Science

In a post-COVID world, society is branching away from pharmaceutical medicine and seeking support that may be less likely to cause side effects.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

Biotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point

Intra-Cellular stock: Shares rocketed more than 23% Tuesday, sending them past their latest buy point on the stock market today.

Investors Business Daily

JNJ Earnings Forecast - Is Pharmaceutical Industry Set for Shake-up?

As pharma titan Johnson & Johnson (JNJ) gears up to unveil its first-quarter results on April 16, 2024, anticipation looms over the pharmaceutical industry. JNJ’s recent acquisitions signal the company’s strategic expansions, and given its history as one of the prominent pharma companies, is JNJ’s forecast as stunning? Let us…

StockNews.com

Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug

Neumora said Monday the FDA put its schizophrenia drug on hold after rabbits experienced convulsions, and the biotech stock plunged.

Investors Business Daily

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Investors Business Daily

The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhere

The Guardian - UK

Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?

Regeneron stock toppled Thursday after the DOJ filed a lawsuit saying the drugmaker fraudulently inflated the prices of its drug, Eylea.

Investors Business Daily

Unbiased Friday Plans Reviews—Who Should Get Friday Plans Viagra And Cialis?

Friday Plans has a stellar 4.3-star rating on Trustpilot, with 40,000+ subscribers praising the convenience, speed, affordability, and effectiveness of their Viagra and Cialis products.

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca CEO’s £18.7m pay approved despite shareholder rebellion

Third of voters reject Pascal Soriot’s deal but some say it is deserved as he had been ‘massively underpaid’

StockNews.com

3 Pharma Stocks Delivering Exciting April Returns

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs, increasing demand for innovative medications, and technological advancements. Therefore, fundamentally strong pharmaceutical stocks Dr. Reddy’s (RDY), Teva Pharmaceutical Industries (TEVA), and AbbVie (ABBV) could be worth adding to your portfolio. Read on.

StockNews.com

3 Biotech Gems Poised for April Breakthroughs

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

StockNews.com

3 A-Rated Pharma Stocks to Boost Your Bottom Line

The pharmaceutical industry is experiencing rapid growth thanks to healthcare demand, regulatory initiatives, and technological adoption in drug discovery and development. Hence, it could be wise to invest in pharma stocks Ipsen (IPSEY), Bristol-Myers (BMY), and Taro Pharmaceutical (TARO) to drive your bottom line. These stocks are rated A (Strong…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

4 Pharma Giants Sparking Investor Interest

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading….

Investors Business Daily

Taser Maker Axon Approaches Latest Buy Point After 13% Surge

Axon stock: The Taser maker is approaching a buy point in today's stock market. Shares are nearing a new high.

StockNews.com

3 Lucrative Pharma Stocks to Diversify Your Investments

The pharma industry’s resilience and long-term prospects are driven by rising healthcare demand, an enhanced focus on precision medicines, and technological advancements. Hence, let’s take a look at pharma stocks Perrigo Company (PRGO), Amneal Pharmaceuticals (AMRX), and Supernus Pharmaceuticals (SUPN), which could diversify your investments. Read on….

Investors Business Daily

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst

Sarepta will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has taken a beating since its last report.

StockNews.com

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

Investors Business Daily

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

The company leads the weight-loss drugs market with its blockbuster, Wegovy. But next-generation drugs are coming.

StockNews.com

Aurora Cannabis (ACB) vs. Merck (MRK): Which Pharma Stock Holds Greater Potential for Investors?

The pharmaceutical industry is poised for robust growth owing to technological advancements and growing healthcare needs. Given this backdrop, let’s analyze Aurora Cannabis (ACB) and Merck & Co. (MRK) to determine which of the two stocks holds greater potential for investors. Read on….

1 … 10 11 12 13

People

Margaret Kaczor Andrew

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.